|Enzymes in Drug Discovery Summit|
Protease Inhibitors in Drug Discovery
Ubiquitin Research and Drug Discovery
Protein Kinases in Drug Discovery
We are pleased to invite you to GTCbio’s 8th Ubiquitin Research & Drug Discovery Conference, which will take place February 22-23, 2018 in San Diego, CA. This conference will provide a forum for researchers from industry and academia to learn about recent advances in basic science and drugs that target the ubiquitin/proteasome system. Hot topics such as autophagy in cancer, developments with deubiquitinating enzymes, and novel drug targets in the ubiquitin system will be covered.
Please join us not only for updates on the latest scientific research, but also for networking sessions between colleagues from both industry and academia in order to get the most comprehensive exchange of ideas.
We hope to see you there!
The 2018 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Affimer® reagents are affinity proteins, based on a small protein scaffold engineered to bind with high specificity and affinity to a range of targets. With a 7 week custom service and an online catalogue, they are used for various applications in diagnostics, drug/biomarker discovery, biotech R&D and as therapeutic agents.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
Carna is a leading provider of protein kinases, drug resistant mutants and related kinase inhibitor drug discovery assay services, including cell-based assays. We also offer an industry leading high-throughput pathway mapping service and cell line development services for the study of protein-protein interactions.